Search
Now showing items 21-30 of 35
Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
(
Oxford University Press
, 2022 , Article)
The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
(
Elsevier
, 2022 , Article)
BackgroundUnderstanding protection conferred by natural SARS-CoV-2 infection versus COVID-19 vaccination is important for informing vaccine mandate decisions. We compared protection conferred by natural infection versus ...
Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
(
Massachusetts Medical Society
, 2022 , Other)
More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
(
Oxford University Press
, 2021 , Article)
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
(
Elsevier
, 2023 , Other)
COVID-19 vaccine antigen dose might affect protection against SARS-CoV-2 infection,1, 2 but direct evidence to quantify this effect is absent. We conducted a matched, retrospective, cohort study using a regression ...
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
(
Oxford Academic
, 2021 , Article)
Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to ...
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
(
Elsevier
, 2023 , Article)
BackgroundProtection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination ...
Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar
(
Springer
, 2023 , Article)
Background: Limited data exists on herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections in migrant populations. This study investigated HSV-1 and HSV-2 seroprevalences and associations among craft and manual ...
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
(2023 , Article)
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ...
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
(
Elsevier
, 2023 , Article)
BackgroundWaning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination ...